Febuxostat: A new treatment for hyperuricaemia in gout

Rheumatology

Volumn 48, Issue SUPPL. 2, 2009, Pages

  Edwards, N Lawrence ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

Adverse events; Allopurinol; Clinical studies; Febuxostat; Gout; sUA target; Urate lowering therapy

Indexed keywords

ALLOPURINOL; COLCHICINE; CYTOCHROME P450 2D6; DESIPRAMINE; FEBUXOSTAT; HYDROCHLOROTHIAZIDE; INDOMETACIN; NAPROXEN; PLACEBO; WARFARIN;

AREA UNDER THE CURVE; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; CONFERENCE PAPER; CREATININE BLOOD LEVEL; DIARRHEA; DIZZINESS; DOSE RESPONSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG EXCRETION; DRUG FATALITY; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG STRUCTURE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FOOD DRUG INTERACTION; GOUT; HEART INFARCTION; HUMAN; HYPERURICEMIA; LIVER FUNCTION; NAUSEA; PRIORITY JOURNAL; SIDE EFFECT; TASTE DISORDER; TREATMENT DURATION; TREATMENT RESPONSE;

ALLOPURINOL; GOUT; GOUT SUPPRESSANTS; HUMANS; HYPERURICEMIA; RANDOMIZED CONTROLLED TRIALS AS TOPIC; THIAZOLES;

EID: 65849386648     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/kep088     Document Type: Conference Paper

References (31)

1. Zhang W, Doherty M, Bardin T et al. EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 2006;65:1312-24.
2. Jordan KM, Cameron JS, Snaith M et al. British Society for Rheumatology and British Health Professionals in Rheumatology guideline for the management of gout. Rheumatology 2007;46:1372-4.
3. Becker MA, Schumacher HR Jr, Wortmann RL et al. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N Engl J Med 2005;353:2450-61.
4. Perez-Ruiz F, Alonso-Ruiz A, Calabozo M, Herrero-Beites A, Garcia-Erauskin G, Ruiz-Lucea E. Efficacy of allopurinol and benzbromarone for the control of hyperuricaemia. A pathogenic approach to the treatment of primary chronic gout. Ann Rheum Dis 1998;57:545-9.
5. Hande KR, Noone RM, Stone WJ. Severe allopurinol toxicity. Description and guidelines for prevention in patients with renal insufficiency. Am J Med 1984;76: 47-56.
6. Horiuchi H, Ota M, Kobayashi M et al. A comparative study on the hypouricemic activity and potency in renal xanthine calculus formation of two xanthine oxidase/xanthine dehydrogenase inhibitors: TEI-6720 and allopurinol in rats. Res Commun Mol Pathol Pharmacol 1999;104:307-19.
7. Takano Y, Hase-Aoki K, Horiuchi H et al. Selectivity of febuxostat, a novel non-purine inhibitor of xanthine oxidase/xanthine dehydrogenase. Life Sci 2005;76:1835-47.
8. Adenuric Summary of Product Characteristics accessed at http://www.emea.europa.eu/humandocs/PDFs/EPAR/adenuric/H-777-PI-en.pdf, (date last accessed 8th April 2009).
9. Khosravan R, Grabowski B, Wu JT, Joseph-Ridge N, Vernillet L. Effect of food or antacid on pharmacokinetics and pharmacodynamics of febuxostat in healthy subjects. Br J Clin Pharmacol 2008;65:355-63.
10. Khosravan R, Grabowski BA, Mayer MD, Wu JT, Joseph-Ridge N, Vemillet L. The effect of mild and moderate hepatic impairment on pharmacokinetics, pharmacodynamics, and safety of febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase. J Clin Pharmacol 2006;46:88-102.
11. Mayer MD, Khosravan R, Vernillet L, Wu JT, Joseph-Ridge N, Mulford DJ. Pharmacokinetics and pharmacodynamics of febuxostat, a new non-purine selective inhibitor of xanthine oxidase in subjects with renal impairment. Am J Ther 2005; 12:22-34.
12. Khosravan R, Kukulka MJ, Wu JT, Joseph-Ridge N, Vernillet L. The effect of age and gender on pharmacokinetics, pharmacodynamics, and safety of febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase. J Clin Pharmacol 2008;48:1014-24.
13. Becker MA, Schumacher HR Jr, Wortmann RL et al. Febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase: A twenty-eight-day, multicenter, phase II, randomized, double-blind, placebo-controlled, dose-response clinical trial examining safety and efficacy in patients with grout. Arthritis Rheum 2005;52:916-23.
14. Schumacher HR Jr, Becker MA, Wortmann RL et al. Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: A 28-week, phase III, randomized, double-blind, parallel-group trial. Arthritis Rheum 2008;59:1540-8.
15. Becker M, MacDonald P, Hunt B, Lademacher C, Joseph-Ridge N. Gout flare incidence in relation to average serum urate during the first year of urate-lowering therapy. Abstract presented at the American College of Rheumatology/Association of Rheumatology Health Professionals (ACR/ARHP) Annual Scientific Meeting, Boston, MA, USA, 6-11 November, 2007. [Abstract No. 758].
16. Schumacher HR, Becker MA, MacDonald PA. Febuxostat versus allopurinol in the treatment of gout in subjects 65 years of age or older. Abstract presented at the Annual European Congress of Rheumatology (EULAR), Barcelona, Spain, 13-16 June 2007. [Abstract No. THU0353].
17. Schumacher H, Becker M, Wortmann R, Lloyd E, MacDonald P, Joseph-Ridge N. The FOCUS trial 48-month interim analysis: Long-term clinical outcomes of treatment with febuxostat in subjects with gout in an ongoing phase 2, open-label extension study. Abstract presented at the Annual European Congress of Rheumatology (EULAR), Amsterdam, the Netherlands, 21-24 June 2006. [Abstract No. OP0130].
18. Whelton A, MacDonald P, Lloyd E. The long-term stability of renal function in hyperuricemic subjects with gout treated with febuxostat. Abstract presented at the American Society of Nephrology (ASN) Annual Meeting, San Francisco, CA, USA, 31 October-5 November 2007. [Abstract No. SA-PO918].
19. Wortmann RL, Becker MA, Schumacher HR. Effect of febuxostat or allopurinol on the clinical manifestations of gout: Reduction in gout flares and tophus size over time in the EXCEL trial. Abstract presented at the American College of Rheumatology/Association of Rheumatology Health Professionals (ACR/ARHP) Annual Scientific Meeting, Washington, DC, USA; 10-15 November 2006. [Abstract No. 1592].
20. Becker M, Schumacher H, MacDonald PA. Urate-lowering therapy in subjects with gout: Interim results from the febuxostat comparative extension long-term study (EXCEL). Abstract presented at the Annual European Congress of Rheumatology (EULAR), Barcelona, Spain, 13-16 June 2007. [Abstract No. THU0339].
21. Collaborative overview of randomised trials of ant platelet therapy - I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists' Collaboration. Br Med J 1994; 308:81-106.
22. Choi HK, Curhan G. Independent impact of gout on mortality and risk for coronary heart disease. Circulation 2007;116:894-900.
23. Krishnan E, Baker JF, Furst DE, Schumacher HR. Gout and the risk of acute myocardial infarction. Arthritis Rheum 2006;54:2688-96.
24. Krishnan E, Svendsen K, Neaton JD, Grandits G, Kuller LH. Long-term cardiovascular mortality among middle-aged men with gout. Arch Intern Med 2008; 168:1104-10.
25. Gagliardi AC, Miname MH, Santos RD. Uric acid: A marker of increased cardiovascular risk. Atherosclerosis 2009;202:11-7.
26. Dawson J, Quinn T, Walters M. Uric acid reduction: A new paradigm in the management of cardiovascular risk? Curr Med Chem 2007;14:1879-86.
27. Baker JF, Krishnan E, Chen L, Schumacher HR. Serum uric acid and cardiovascular disease: Recent developments, and where do they leave us? Am J Med 2005;118: 816-26.
28. Niskanen LK, Laaksonen DE, Nyyssonen K et al. Uric acid level as a risk factor for cardiovascular and all-cause mortality in middle-aged men: A prospective cohort study. Arch Intern Med 2004;164:1546-51.
29. Bos MJ, Koudstaal PJ, Hofman A, Witteman JC, Breteler MM. Uric acid is a risk factor for myocardial infarction and stroke: The Rotterdam study. Stroke 2006; 37:1503-7.
30. Puig JG, Martinez MA. Hyperuricemia, gout and the metabolic syndrome. Curr Opin Rheumatol 2008;20:187-91.
31. Vazquez-Mellado J, Garcia CG, Vazquez SG et al. Metabolic syndrome and ischemic heart disease in gout. J Clin Rheumatol 2004;10:105-9.